US Approves Drug for Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has approved a drug for pancreatic cancer, potentially ushering in a new era in the management of one of the most lethal forms of the disease.

Clinical trials showed that the drug was able to double the survival period for a specific group of patients.

Kyle Diamantas, an official at the FDA, said in a statement that the drug provides “a new, critically important option for patients facing a very difficult type of cancer whose treatment has posed a major challenge throughout history.”

Although the oral medication does not cure the disease, it has sparked enthusiasm among oncologists and patient advocacy groups, as it may offer patients with this aggressive form of cancer a chance to live a few additional months.

Half of the patients who received the drug survived for more than 13 months, a duration twice as long as that of the group treated with chemotherapy.

These results have received widespread acclaim from the medical community and represent the first major breakthrough in confronting this type of cancer in decades.

They also offer hope for the development of treatments for other patients, as the drug targets a protein found in various types of cancer that was previously believed to be resistant to therapeutic targeting.